Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.59)
# 798
Out of 5,182 analysts
146
Total ratings
53.85%
Success rate
4.35%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group | Maintains: Outperform | $385 → $405 | $355.60 | +13.89% | 19 | Apr 22, 2026 | |
| GRDN Guardian Pharmacy Services | Maintains: Outperform | $35 → $38 | $36.33 | +4.61% | 2 | Mar 12, 2026 | |
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $35.30 | +18.98% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.78 | +21.21% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.06 | +96.40% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $379.01 | +31.92% | 14 | Feb 27, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $476.27 | +13.38% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $13.74 | +1.93% | 3 | Jan 22, 2026 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $40.45 | +6.30% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $216.71 | +43.05% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $278.04 | +34.87% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $30.15 | +22.72% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $189.15 | -11.18% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $94.62 | +53.24% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $2.68 | +86.57% | 10 | Jul 25, 2024 |
UnitedHealth Group
Apr 22, 2026
Maintains: Outperform
Price Target: $385 → $405
Current: $355.60
Upside: +13.89%
Guardian Pharmacy Services
Mar 12, 2026
Maintains: Outperform
Price Target: $35 → $38
Current: $36.33
Upside: +4.61%
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $35.30
Upside: +18.98%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.78
Upside: +21.21%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.06
Upside: +96.40%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $379.01
Upside: +31.92%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $476.27
Upside: +13.38%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $13.74
Upside: +1.93%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $40.45
Upside: +6.30%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $216.71
Upside: +43.05%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $278.04
Upside: +34.87%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $30.15
Upside: +22.72%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $189.15
Upside: -11.18%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $94.62
Upside: +53.24%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $2.68
Upside: +86.57%